EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

NEXT STORY
Apollomics, Inc. Appoints Fabio M. Benedetti, M.D. as Chief Medical Officer
PREV STORY
Teleflex Announces Multiple Data Presentations from Studies of the UroLift® System Treatment for Enlarged Prostate at the American Urological Association 2019 Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors

First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based ...

author_avatar
NASDAQ Market News

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

author_avatar
NASDAQ Market News

Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting

author_avatar
NASDAQ Market News